Horizon CEO: Growth Driver Tepezza 'Still At A Fraction' Of Expected Peak Sales

TL;DR

Horizon Therapeutics had a successful Q3 with strong revenue growth, driven by the performance of their thyroid eye disease drug Topeza and their uncontrolled gout medicine Chrystexa.

Transcript

leading medical sector name horizon therapeutics on november 3rd reported a beat and raised quarter for q3 top line growth of 63 was strong but earnings grew just one percent but that was compared with a tough year-over-year comp of 172 in the september 2020 quarter here now with details on the report and what's ahead for horizon is ceo tim walbert... Read More

Key Insights

• 💪 Horizon Therapeutics' Q3 report showed strong revenue growth, driven by the success of Topeza and Chrystexa.
• ⛽ The company has a significant focus on expanding its lineup and pipeline to fuel future growth.
• 😃 They announced positive results for prostexa in uncontrolled gout treatment and started a new trial for chronic thyroid eye disease.
• 👻 Horizon Therapeutics' manufacturing facility in Ireland provides them control over their pipeline and allows for the production of their own medicines.
• 👶 The CFO transition was announced, with the current CFO retiring and the new CFO, who has been with the company for five years, stepping in.

Questions & Answers

Q: What were Horizon Therapeutics' revenue and earnings growth for Q3?

Horizon Therapeutics had a 63% increase in revenue for Q3, while earnings grew by 1%, compared to a tough year-over-year comparison.

Q: How did Horizon Therapeutics' thyroid eye disease drug Topeza perform in Q3?

Topeza had sales of $616 million in Q3, with a growth rate of 115%. It continues to deliver strong results for the company.

Q: What other medicine showed strong growth for Horizon Therapeutics in Q3?

Chrystexa, their medicine for uncontrolled gout, experienced a 46% year-over-year growth in Q3.

Q: How is Horizon Therapeutics expanding its lineup and pipeline?

Horizon Therapeutics is conducting trials for Topaza and prostexa, expecting exciting results in the future. They also have over 20 programs in their pipeline, including five new phase two programs starting next year.

Summary & Key Takeaways

• Horizon Therapeutics reported a beat and raised quarter for Q3 with a 63% increase in revenue and 1% growth in earnings compared to a tough year-over-year comparison.

• Topeza, their thyroid eye disease drug, saw sales of $616 million with a growth of 115% in the quarter, while Chrystexa, their uncontrolled gout medicine, also experienced strong growth with a 46% year-over-year increase.

• The company is focused on expanding their lineup with ongoing trials for Topaza and prostexa, as well as a pipeline of over 20 programs, including five new phase two programs starting next year.